BRPI0511398A - anhydrous pharmaceutical composition for the treatment of psoriasis and use of a silicon agent - Google Patents

anhydrous pharmaceutical composition for the treatment of psoriasis and use of a silicon agent

Info

Publication number
BRPI0511398A
BRPI0511398A BRPI0511398-9A BRPI0511398A BRPI0511398A BR PI0511398 A BRPI0511398 A BR PI0511398A BR PI0511398 A BRPI0511398 A BR PI0511398A BR PI0511398 A BRPI0511398 A BR PI0511398A
Authority
BR
Brazil
Prior art keywords
psoriasis
pharmaceutical composition
treatment
anhydrous pharmaceutical
agent
Prior art date
Application number
BRPI0511398-9A
Other languages
Portuguese (pt)
Inventor
Leslie Zanutto
Sandrine Orsoni
Emilie Tonglet
Claire Mallard
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0406610A external-priority patent/FR2871695B1/en
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BRPI0511398A publication Critical patent/BRPI0511398A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/20—Deposition of semiconductor materials on a substrate, e.g. epitaxial growth solid phase epitaxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO FARMACêUTICA ANIDRA PARA O TRATAMENTO DA PSORìASE E USO DE UM AGENTE SILICONADO. A presente invenção trata de uma composição farmacêutica anidra que compreende um agente siliconado que compreende pelo menos um elastómero organopolissiloxano e, como princípios ativos, a vitamina D ou um derivado da vitamina D e um corticosteróide. Ela trata também do processo para preparar essa composição e de seu uso para o tratamento tópico da psoríase e de outras doenças da pele.PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND USE OF A SILICONED AGENT. The present invention relates to an anhydrous pharmaceutical composition comprising a silicon agent comprising at least one organopolysiloxane elastomer and, as active ingredients, vitamin D or a vitamin D derivative and a corticosteroid. It also addresses the process for preparing this composition and its use for the topical treatment of psoriasis and other skin conditions.

BRPI0511398-9A 2004-06-17 2005-06-15 anhydrous pharmaceutical composition for the treatment of psoriasis and use of a silicon agent BRPI0511398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0406610A FR2871695B1 (en) 2004-06-17 2004-06-17 PHARMACEUTICAL COMPOSITION COMPRISING A SILICONE AGENT AND TWO SOLUBILIZED ACTIVE INGREDIENTS
US10/951,887 US7901698B2 (en) 2004-06-17 2004-09-29 Pharmaceutical compositions comprising silicones and two solubilized active principles
PCT/EP2005/007974 WO2005123092A1 (en) 2004-06-17 2005-06-15 Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof

Publications (1)

Publication Number Publication Date
BRPI0511398A true BRPI0511398A (en) 2007-12-04

Family

ID=35509451

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511398-9A BRPI0511398A (en) 2004-06-17 2005-06-15 anhydrous pharmaceutical composition for the treatment of psoriasis and use of a silicon agent

Country Status (7)

Country Link
EP (1) EP1758589A1 (en)
JP (1) JP2008502647A (en)
KR (1) KR20070027587A (en)
AU (1) AU2005253735A1 (en)
BR (1) BRPI0511398A (en)
CA (1) CA2567636A1 (en)
WO (1) WO2005123092A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867682B1 (en) * 2004-03-22 2009-06-05 Galderma Res & Dev ANHYDROUS PHARMACEUTICAL COMPOSITION COMPRISING A SILICONE AGENT AND A SOLUBILIZED ACTIVE INGREDIENT.
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20100184714A1 (en) 2007-07-11 2010-07-22 Victor Albert Raul Compositions For Delivering A Drug
WO2011006100A1 (en) * 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Method of wound healing and scar modulation
HUE045467T2 (en) 2011-03-14 2020-01-28 Drug Delivery Solutions Ltd An ophthalmic composition
CN104271160B (en) * 2012-04-27 2017-08-08 道康宁公司 Comprising the excipient based on organosilicon with by topical preparation's composition of active delivery to substrate
TW201636025A (en) * 2015-04-15 2016-10-16 Maruho Kk Pharmaceutical composition for skin
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
FR2719220A1 (en) * 1994-04-29 1995-11-03 Lafon Labor New galenic form for transdermal administration.
FR2737118B1 (en) * 1995-07-28 1997-09-05 Oreal DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND USE
FR2738745B1 (en) * 1995-09-15 1997-10-24 Cird Galderma NOVEL COMPOSITIONS BASED ON A SYNERGETIC MIXTURE BETWEEN AT LEAST ONE VDR LIGAND AND A RETINOID, AND USES THEREOF
IT1302275B1 (en) * 1998-09-25 2000-09-05 Giorgio Panin VITAMIN AND ACETATE HYDROPHOBIC GEL FORMULATION FOR TOPICAL APPLICATION.
KR100694526B1 (en) * 1999-04-23 2007-03-13 레오 파마 에이/에스 Pharmaceutical composition
DE10024413A1 (en) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmaceutical and / or cosmetic preparation

Also Published As

Publication number Publication date
CA2567636A1 (en) 2005-12-29
KR20070027587A (en) 2007-03-09
WO2005123092A1 (en) 2005-12-29
JP2008502647A (en) 2008-01-31
EP1758589A1 (en) 2007-03-07
AU2005253735A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
BRPI0511398A (en) anhydrous pharmaceutical composition for the treatment of psoriasis and use of a silicon agent
AR049518A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A SILICONE AGENT AND TWO SOLUBILIZED ACTIVE PRINCIPLES
BRPI1007379B8 (en) pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
BRPI0809164B8 (en) COMPOSITION FOR TOPICAL ADMINISTRATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOSITION
BR112015023922A2 (en) pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of using these
BRPI0517481A (en) method for treating, controlling or preventing a protozoan parasitic disease or disorder, and, pharmaceutical composition
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
BR112019009529A2 (en) new quinoline derivatives
BRPI0508540A (en) compound, pharmaceutical composition, and use of a compound
BRPI0622054B8 (en) compound and pharmaceutical composition
BRPI0822162B8 (en) pharmaceutical composition for topical treatment of nail disease or nail bed
BR112014016672A2 (en) carbamate compounds and their preparation and use
BRPI0518255A2 (en) Methods of treating or preventing a central nervous system injury to reduce or prevent an adverse effect, and pharmaceutical composition
WO2004089357A3 (en) Anti-fungal formulation of triterpene and essential oil
BR112012006686B8 (en) substituted amide compounds, pharmaceutical compositions containing said compounds, and their use to prevent and/or treat diseases caused by Lpa
BRPI0410306A (en) methods for treating, controlling or preventing a specific cancer, treating, controlling or preventing a disease associated with unwanted angiogenesis, and for reducing or preventing an adverse effect, pharmaceutical composition, and kit.
BRPI0518999A2 (en) compositions and methods for treating nail unit conditions
CO5640037A2 (en) DERIVATIVES OF QUINAZOLINE FOR THE TREATMENT OF CANCER
GT200900154A (en) DERIVATIVES OF 2,3-DIHYDROIMIDOZO [1,2-C] QUINIZOLINA SUBSTITUTED FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
BR112022001324A2 (en) Compound, pharmaceutical composition and method for treating a p38 map kinase-mediated disease in a subject in need thereof
BR112021022758A2 (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, their compositions and methods of treatment therewith
BRPI1009842B8 (en) use of tlr9 agonist and tlr2/6 agonist in the preparation of a pharmaceutical composition for treating, inhibiting or attenuating a microbial infection, as well as a pharmaceutically acceptable composition comprising said agonists
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
CO2020001242A2 (en) Dihydrooxadiazinones

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired